Back to News
Market Impact: 0.2
BTIG Initiates Coverage of ORIC Pharmaceuticals at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
BTIG initiated coverage of ORIC Pharmaceuticals (NASDAQGS: ORIC) on September 23, 2026, with a Buy recommendation. The initiation is a positive external endorsement for the U.S.-based biotechnology company, although the article provides no price target, valuation rationale, or clinical-development details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ORIC0.50
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- Meta's standoff with Amazon over Muse could be a sign of things to come
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals
- What Makes Financial Data Ready for AI Research?